Digipharm is a limited company (ltd) registered in Zug, Switzerland. The Digipharm team is located globally however several of the core team members are based in Switzerland.
Digipharms’ solutions aim to accelerate the much needed restructuring of healthcare delivery systems to a value based approach by utilising smart contracts and revolutionary blockchain technology. Digipharm aims to overcome barriers to innovative pricing and patient access, reduce costs for all stakeholders and bypass infrastructural limitation to drive value improvement, incentivise innovation and expedite the transformation to personalised healthcare.
When assessing new drugs and treatments, health authorities and insurers or ‘payers’ are often required to make the difficult decision of whether to reimburse costly pharmacological therapies and provide access for patients while taking into account their limited resources. Following regulatory approval, manufacturers are often required to propose patient access schemes or value-based pricing agreements to payers in order to allow both the payers and manufacturers to share the ‘risk' or ‘uncertainty’ of administering new therapies beyond clinical studies to a wider patient population. Unfortunately, most healthcare providers or payers around the world lack the relevant infrastructure to track and implement outcomes-based pricing agreements, and so are shy in adopting such innovative pricing contracts and policies. This results in innovative pharmacological therapies being denied to patients who are most at need, an opportunity missed to decrease the long term economic and disease burden on health systems and a barrier to reimbursement for manufacturers.

Real world evidence (RWE) is playing an increasingly influential role in informing decision making within the healthcare industry and is crucial to informing value-based healthcare. Yet the delay of RWE outputs, the expenses of data access and the current methods of data collection negate many of the benefits of utilising these rich data resources. The lack of easily accessible and comprehensive RWE currently prevents stakeholders in healthcare to evaluate the real time performance and value provided by therapy in real life clinical practice as part of a value-based healthcare delivery system.
⋅ Patients: The person receiving medical treatment
⋅ Payers: The entity responsible for the financial settlement of
healthcare products or services ⋅ Manufacturers: Typically pharmaceutical companies that are responsible for developing and marketing therapies
⋅ Providers: Healthcare professionals that are authorised to practice by the appropriate regulatory bodies
Value-based pricing is a pricing strategy that determines the price of a service or product based on the perceived benefit or value it provides to the customer.
Value based healthcare encompasses a model where healthcare systems pay providers according to patient outcome, rather than the volume of treatment provided or the number of interactions with the healthcare system.
⋅ The level of reimbursement is linked to the value provided.
⋅ Risk is shared between payer and manufacturer.
⋅ Improvements in patients outcomes and maximisation of benefits relative to net spend
⋅ Possibility to provide market access for therapies where the risk or uncertainty of providing treatment is high
⋅ Incentives and rewards for improving patient outcomes
⋅ Counteracts supplier-induced demand
It is defined as any evidence that is derived from clinical settings in regards to the outcomes associated with the provision of a therapy in a day-to-day context beyond clinical research studies and not collected in conventional randomised clinical trials, i.e. safety reporting data, claims data, patient reported outcomes or efficacy data.
⋅ Informing payer decision making (e.g. reimbursement and coverage decisions by payers or regulatory agencies)
⋅ Business planning and identification of unmet needs
⋅ Development of product strategies by pharmaceutical companies
⋅ Identifying patient groups or disease areas with unmet needs
⋅ To remedy the limitations of randomised clinical trials
⋅ The development of Health Technology Assessment dossiers by manufacturers and informing the pharmacoeconomic evaluation of health technology or programmes
⋅ Supporting clinical guidelines and the development of decision support tools in clinical practise including the tracking of patient outcomes and safety data
⋅ Informing clinical trial design
⋅ Disease registries and data banks
⋅ Collection, distribution and availability of RWE
⋅ Currently static, retrospective data is used due to high costs and resource use associated with generating or collecting observational data
⋅ Expensive to access
⋅ Inconsistency and incompatibility of data arising from numerous sources
⋅ Disparities in formatting methodologies between data collection centres
⋅ Concerns over the privacy and security of patient data
⋅ Fragmented data from a variety of sources for each patient, that is time consuming to amalgamate and present in a consistent manner
⋅ Absence of potentially useful information
⋅ Permission not provided by patient due to lack of incentives
⋅ Patients do not have access to up-to-date RWE
Reimburse is a fully independent platform that facilitates innovative pricing solutions and personalised reimbursement of health technology on a ‘fee for performance' basis for the mutual benefit of patients, payers and manufacturers. The Reimburse platform will also be used to enable the application of broader value-based contracting models such as bundled payments. The underlying technology eliminates the requirement for manual processing of contracting agreements and automates outcomes/patient tracking thus reducing administrative costs and resource use for all stakeholders that participate within the Reimburse ecosystem.
Insights is the world's first ‘live’ RWE platform. Allowing the utilisation of real world evidence (RWE) as soon as it becomes available, to inform healthcare related decision making and health related research. Insights will provide a symbiotic solution with Reimburse to complement the progressive transformation towards value-based healthcare delivery systems. The Insights platform aims to reward and incentivise patients for contributing their data, something which is not currently done.
On the Insights platform, patients will be able to share their health related data and be incentivised for doing so. The Insights platform will provide the opportunity for patients to analyse recent real world benefits of the treatment options available to them, the ability to compare outcomes at different treatment centres and would provide valuable information in regards to the prognosis of patients with similar characteristics to themselves. Patients will also be a key stakeholder in the functionality of the MyHealth platform.
Payers will use the Reimburse platform for creating innovative reimbursement models with manufacturers and providers, enabling them to decrease their expenditure on treatment that does not provide value and obtaining greater benefits for an equivalent net monetary spend. Furthermore, payers will use the Reimburse platform for secure data processing and to obtain a real time overview of treatment uptake and treatment duration to assist budget monitoring and time driven activity based costing. In the future, it is possible this platform will be used for automated payment mechanism subject to regulatory and legal approval.

The Insights platform will give payers a real time overview of patient outcomes to inform decision making and the development of clinical or regulatory guidelines. Moreover payers will use Insights for anticipating health related trends in real time and for informing the economic evaluation of health technology process. To summarise, payers will use Insights for access to full spectrum RWE.
Manufacturers will use Reimburse as a global platform to facilitate and manage innovative pricing agreements and personalised reimbursement solutions that guarantees the timely processing and monitoring of innovative pricing agreements.

Manufacturers will use the Insights platform to receive global oversight with no delay, save costs (by eliminating the need for lengthy and expensive observational studies), inform drug development at all stages of medicinal lifecycle and to inform payer submissions. In addition, Manufacturers will be able to use the Insights platform to create integrated analysis of costs and outcomes in combination with Reimburse.
MyHealth is a pipeline application (subject to regulatory and legal considerations) that will be used in collaboration with payers and providers to track patients’ health related behaviour and reward or incentivise them accordingly. The requirement for this platform is the proven long term financial impact of incentivising patients with their healthcare management and the importance of treatment adherence to the successful implementation of value-based healthcare. Data collection on the MyHealth platform will allow health insurance providers to identify lower risk patients and offer subsequent reductions in health insurance premiums.
Evolve is a pipeline platform (subject to regulatory and legal considerations) that will propose new methods for crowdfunding medical innovation. Funds will be raised via initial coin offerings (ICO) and digital assetization to support early proof-of-concept research, ex-vivo studies and pre-clinical studies. The Evolve platform is likely to become a valuable addition to early funding phases in medical innovation and drug development especially for orphan diseases.
Digipharm is currently in both discussions and planning stages for testbeds with several interested parties that may not be disclosed at this moment in time.
⋅ Decentralised
⋅ Transparent
⋅ Security conscious
⋅ Immutable
⋅ Cryptographically encrypted
⋅ Privacy
Smart contracts are self-executing pieces of code that digitally facilitate, verify or enforce the terms of a predetermined agreement. These contracts allow transactions to be carried out between parties anonymously with no need for external enforcement or action. All transactions based on smart contracts are published to the blockchains ledger and provide both transparency and immutability.
Digipharm(D PH)tokens(E RC-20 )willbeusedtopaylicense/accessfeeson Digipharm platforms. Access fees will invariably be determined and stipulated in USD value and the quantity of tokens required will depend on the type of access (manufacturer, patient, payer or provider) combined with the form of interaction required. The quantity of tokens required for such interactions is subject to change, relative to the market value of DPH.

DPH tokens have a fixed supply of 100,000,000

Payers/manufacturers will be required to use DPH tokens to initiate or execute smart contracts within the Reimburse module and to enrol individual patients on these smart contracts, i.e. DPH tokens will be used to facilitate the process of annexing patients to innovative pricing and reimbursement agreements.

DPH will be used as the utility token to power each interaction with the Insights database by healthcare stakeholders i.e. DPH tokens will be used for access rights or specific data requests from the Insights platform.